Efficacy and safety of sodium–glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in japanese patients with type 2 diabetes mellitus; fukuoka study of ipragliflozin (FUSION)

Endocrine Journal

Volumn 65, Issue 8, 2018, Pages 859-867

  Nomiyama, Takashi ^a   Shimono, Dai ^b   Horikawa, Tsuyoshi ^a   Fujimura, Yuki ^a   Ohsako, Tomohiro ^a   Terawaki, Yuichi ^a   Fukuda, Takashi ^a   Motonaga, Ryoko ^a   Tanabe, Makito ^a   Yanase, Toshihiko ^a   Nawata, Hajime ^c   Takahashi, Hiroyuki ^c   Yanagida, Ikumi ^c   Ono, Junko ^c   Kogawa, Kazuhiko ^c   Muta, Kazuo ^c   Arase, Koichi ^c   Oba, Koichi ^c   Murase, Kunitaka ^c   Hamanoue, Nobuya ^c   Minezaki, Midori ^c   Imamura, Mitsuhide ^c   Yoshida, Ryoko ^c   Yatabe, Sakon ^c   Komatsu, Shiho ^c   Maruyama, Syunichiro ^c   Futata, Tetsuhiro ^c   Umei, Toshihiko ^c   Noda, Tomohiro ^c   Hyodo, Tomoko ^c   Tsutsumi, Yoko ^c   Takeda, Yumi ^c   Hatta, Yumiko ^c   Fukuda, Yusuke ^c   Fujihara, Yuya ^c   more..

^a FUKUOKA UNIVERSITY   (Japan)

^b Futata Tetsuhiro Clinic   (Japan)

^c NONE

Author keywords

Adiponectin; Baseline hemoglobin a1c; C peptide; Glucose co transporter 2 inhibitor; High density lipoprotein cholesterol; Sodium

Indexed keywords

ADIPONECTIN; C PEPTIDE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IPRAGLIFLOZIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; GLUCOSIDE; THIOPHENE DERIVATIVE;

ABDOMINAL DISTENSION; ADULT; AGED; ALOPECIA; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; BRAIN HEMORRHAGE; CARDIOVASCULAR PARAMETERS; CLINICAL EFFECTIVENESS; CONSTIPATION; CYSTITIS; DIZZINESS; DRUG ERUPTION; DRUG SAFETY; DYSURIA; ECHOGRAPHY; ECZEMA; FEMALE; FOLLICULITIS; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART ARRHYTHMIA; HUMAN; HYPOGLYCEMIA; HYPOTENSION; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOME ASSESSMENT; POLLAKISURIA; POLYDIPSIA; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PRURITUS; PULSE WAVE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UNIVERSITY HOSPITAL; URTICARIA; VAGINA CANDIDIASIS; VAGINAL BURNING SENSATION; VULVA DISEASE; BLOOD; CLINICAL TRIAL; MIDDLE AGED; YOUNG ADULT;

ADIPONECTIN; ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; THIOPHENES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85052620222     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ18-0022     Document Type: Article

References (23)

1. Tanabe M, Motonaga R, Terawaki Y, Nomiyama T, Yanase T (2017) Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: a retrospective cohort study using a Japanese hospital database. J Diabetes Investig 8: 227–234.
2. Abdul-Ghani MA, DeFronzo RA, Norton L (2013) Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30–50% of filtrated glucose load in humans. Diabetes 62: 3324–3328.
3. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, et al. (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373: 2117– 2128.
4. Kaku K, Lee J, Mattheus M, Kaspers S, George J, et al. (2017) Empagliflozin and cardiovascular outcomes in asian patients with type 2 diabetes and established cardiovascular disease—results from EMPA-REG OUTCOME®. Circ J 81: 227–234.
5. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, et al. (2012) Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol 385: 423–436.
6. Lu CH, Min KW, Chuang LM, Kokubo S, Yoshida S, et al. (2016) Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: results of phase 3 ranomized, placebo-controlled, double-blind, multicenter trial. J Diabetes Investig 7: 366–373.
7. Yanase T, Nasu S, Mukuta Y, Shimizu Y, Nishihara T, et al. (2006) Evaluation of a new carotid intima-media thickness measurement by b-mode ultrasonography using an innovative measurement software, intimascope. Am J Hypertens 19: 1206–1212.
8. Ogawa O, Hiraoka K, Watanabe T, Kinoshita J, Kawasumi M, et al. (2008) Diabetic retinopathy is associated with pulse wave velocity, not with the augmentation index of pulse wave form. Cardiovasc Diabetol 7: 11.
9. Kashiwagi A, Kazuta K, Yoshida S, Nagase I (2014) Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipregliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig 5: 382–391.
10. Terauchi Y, Yokote K, Nakamura I, Sugamori H (2016) Real-world evidence for the safety of ipraglifrozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of post-marketing surveillance study. Expert Opinion Pharmacother 17: 1995– 2003.
11. Yamamoto C, Miyoshi H, Ono K, Sugawara H, Kameda R, et al. (2016) Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy. Endocr J 63: 589–596.
12. Nomiyama T, Akehi Y, Takenoshita H, Nagaishi R, Terawaki Y, et al. (2012) Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 95: e27–e28.
13. Ishihara H, Yamaguchi S, Nakao I, Okitsu A, Asahina S (2016) Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabete mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study. Diabetes Obes Metab 18: 1207–1216.
14. Takahara M, Shiraiwa T, Matsuoka TA, Katakami N, Shimomura I (2015) Ameliorated pancreatic β cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin. Endocr J 62: 77–86.
15. Holden SE, Jenkins-Jones S, Morgan CL, Schernthaner G, Currie CJ (2015) Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer. Diabetes Obes Metab 17: 350–362.
16. Pedersen MG, Ahlstedt I, EI Hachmane MF, Gopel SO (2016) Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical stimulations of human A-cells. Sci Rep 6: 31214.
17. Kaku K, Kadowaki T, Terauchi Y, Okamoto T, Sato A, et al. (2015) Sitagliptin improves glycemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance. Diabetes Obes Metab 17: 1033–1041.
18. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, et al. (2013) Biguanides suppress hepatic glucagon signaling by decreasing production of cyclic AMP. Nature 494: 256– 260.
19. Vallianou NG, Geladari E, Kazazis CE (2017) SGLT-2 inhibitors: their pleiotropic properties. Diabetes Metab Syndr 11: 311–315.
20. Hayashi T, Fukui T, Nakanishi N, Yamamoto S, Tomoyasu M, et al. (2017) Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol 16: 8.
21. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, et al. (1998) Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316: 823– 828.
22. Maeda N, Funahashi T, Shimomura I (2013) Cardiovascular-metabolic impact of adiponectin and aqua-porin. Endocr J 60: 251–259.
23. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, et al. (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377: 644–657.